caa a22 4500 477056938 CHVBK 20180405111348.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/s002280050144 doi (NATIONALLICENCE)springer-10.1007/s002280050144 Effects of mefloquine alone and with alcohol on psychomotor and driving performance [Elektronische Daten] [E. F. P. M. Vuurman, N. D. Muntjewerff, M. M. C. Uiterwijk, L. M. A. van Veggel, C. Crevoisier, L. Haglund, M. Kinzig, J. F. O'Hanlon] Objective: To determine whether mefloquine, a quinoline antimalarial drug, affects psychomotor and actual driving performance when given in a prophylactic regimen, alone or in combination with alcohol. Methods: Forty male and female volunteers were randomly assigned in equal numbers to two groups, and were treated double-blind for one month with mefloquine and placebo. The medication was taken in a 250 mg dose on the evenings of Days 1, 2, 3, 8, 15, 22 and 29. Testing was done on Days 4, 23 and 30, the latter after repeated doses of alcohol sufficient to sustain a blood concentration of about 0.35 mg ⋅ml−1. Two real driving tests were used to measure prolonged (1 h) road tracking and car following performance. Critical Flicker/Fusion Frequency (CFF), critical instability tracking and body sway were also measured in the laboratory. Results: Mefloquine caused no significant impairment in any test at any time relative to placebo. It significantly improved road tracking performance on Day 4. A significant interaction between prior treatment and alcohol was found in the body sway test, as the alcohol-induced change was less after mefloquine than placebo. The sensitivity of the driving test and the CFF test were shown by the significant overall effect of alcohol which did not discriminate between the two prior treatments. Conclusion: Mefloquine did not impair driving performance but rather improved it in the longer test, suggesting that the drug may possess psychostimulating properties. Springer-Verlag Berlin Heidelberg, 1996 Key words Mefloquine nationallicence Alcohol interactions nationallicence antimalarial drugs nationallicence driving performance nationallicence SDLP nationallicence Vuurman E. F. P. M. Department of Psychiatry and Neuropsychology, University of Limburg, Maastricht, The Netherlands, NL aut Muntjewerff N. D. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut Uiterwijk M. M. C. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut van Veggel L. M. A. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut Crevoisier C. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland, CH aut Haglund L. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland, CH aut Kinzig M. Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany, DE aut O'Hanlon J. F. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut https://doi.org/10.1007/s002280050144 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050144 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vuurman E. F. P. M. Department of Psychiatry and Neuropsychology, University of Limburg, Maastricht, The Netherlands, NL aut NATIONALLICENCE 700 1- Muntjewerff N. D. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut NATIONALLICENCE 700 1- Uiterwijk M. M. C. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut NATIONALLICENCE 700 1- van Veggel L. M. A. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut NATIONALLICENCE 700 1- Crevoisier C. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland, CH aut NATIONALLICENCE 700 1- Haglund L. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland, CH aut NATIONALLICENCE 700 1- Kinzig M. Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany, DE aut NATIONALLICENCE 700 1- O'Hanlon J. F. Institute for Human Psychopharmacology, University of Limburg, Abstract 2A, NL-6211 LS Maastricht, The Netherlands, NL aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer